Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celllymphomastagenasaluln
  Phrases that lowered it: methotrexatehiv infectionefficacygoodsafety
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports with a death: 15.8% (lowers risk) · Drug's FDA history
• Maximum age: 70 (lowers risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 14 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 27182 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 12 (raises risk) · Sponsor's track record
• Sponsor's past trials: 2 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 73.0% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 139029 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens NCT02533323 · started 2012 · scored riskier than 27% of active trials terminated
• Sandwich Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL NCT02520479 · started 2013 · scored riskier than 33% of active trials terminated
• Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma NCT04004572 · started 2019 · scored riskier than 43% of active trials completed
• Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage NCT02359162 · started 2015 · scored riskier than 17% of active trials terminated
• Stage I/II Nasal NK Cell Lymphoma NCT01321008 · started 2011 · scored riskier than 96% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.